VectorLogics Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

VectorLogics General Information

Description

Developer of virus based cancer therapies and therapeutic vaccines for viral liver diseases. The company utilizes IBDV technology for research on Viral hepatitis and Hepatocellular carcinoma. The company commercializes products for Cancer Virotherapy, Cancer Vaccines, Prophylactic and Therapeutic Vaccines.

Contact Information

Website
www.vectorlogics.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 550 11th Street South
  • Birmingham, AL 35294
  • United States
+1 (301)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
DNAtrix
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 550 11th Street South
  • Birmingham, AL 35294
  • United States
+1 (301)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

VectorLogics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Merger/Acquisition 23-Oct-2012 Completed Generating Revenue
10. Grant 22-Jul-2009 Completed Startup
9. Grant 17-Sep-2008 Completed Startup
8. Grant 21-Feb-2008 Completed Startup
7. Grant 01-Jan-2008 Completed Startup
6. Grant 01-Jan-2007 Completed Startup
5. Grant 01-Jan-2006 Completed Startup
4. Grant 01-Jan-2002 Completed Startup
3. Grant 01-Jan-2001 $170K Completed Startup
2. Grant 01-Jan-1999 $350K Completed Startup
To view VectorLogics’s complete valuation and funding history, request access »

VectorLogics Patents

  • 40

    Total Documents Applications and Grants

  • Total Patents Families

  • 3

    Granted

  • Pending

  • Expiring in next 12 mo

VectorLogics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2009117656-A2 Capsid-incorporated antigen for novel adenovirus vaccine Inactive 21-Mar-2008
WO-2009117656-A3 Capsid-incorporated antigen for novel adenovirus vaccine Inactive 21-Mar-2008
WO-2009117656-A9 Capsid-incorporated antigen for novel adenovirus vaccine Inactive 21-Mar-2008
DE-602008004476-D1 Cells for adenovirus vector and protein production Active 09-Mar-2007
EP-2132300-A2 Cells for adenovirus vector and protein production Active 09-Mar-2007 C12N7/00
To view VectorLogics’s complete patent history, request access »

VectorLogics Former Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds
Greer Capital Advisors Venture Capital Minority
To view VectorLogics’s complete investors history, request access »

Ready to get started?

Request a free trial

VectorLogics FAQs

  • Where is VectorLogics headquartered?

    VectorLogics is headquartered in Birmingham, AL.

  • What industry is VectorLogics in?

    VectorLogics’s primary industry is Drug Discovery.

  • Is VectorLogics a private or public company?

    VectorLogics is a Private company.

  • What is VectorLogics’s current revenue?

    The current revenue for VectorLogics is .

  • Who are VectorLogics’s investors?

    Greer Capital Advisors has invested in VectorLogics.

  • When was VectorLogics acquired?

    VectorLogics was acquired on 23-Oct-2012.

  • Who acquired VectorLogics?

    VectorLogics was acquired by DNAtrix.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process